195 related articles for article (PubMed ID: 17434236)
1. Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain.
Wu C; Li YL; Wang ZM; Li Z; Zhang TX; Wei Z
Lung Cancer; 2007 Sep; 57(3):359-64. PubMed ID: 17434236
[TBL] [Abstract][Full Text] [Related]
2. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
[TBL] [Abstract][Full Text] [Related]
3. Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers.
Lee DH; Han JY; Lee HG; Lee JJ; Lee EK; Kim HY; Kim HK; Hong EK; Lee JS
Clin Cancer Res; 2005 Apr; 11(8):3032-7. PubMed ID: 15837758
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of gefitinib as a first-line therapy in elderly patients with pulmonary adenocarcinoma: West Japan Thoracic Oncology Group Study 0402.
Kobayashi M; Matsui K; Katakami N; Takeda K; Moriyama A; Iwamoto Y; Takada M; Yoshioka H; Sueoka-Aragane N; Nakagawa K;
Jpn J Clin Oncol; 2011 Aug; 41(8):948-52. PubMed ID: 21715363
[TBL] [Abstract][Full Text] [Related]
5. Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer.
Hotta K; Kiura K; Ueoka H; Tabata M; Fujiwara K; Kozuki T; Okada T; Hisamoto A; Tanimoto M
Lung Cancer; 2004 Nov; 46(2):255-61. PubMed ID: 15474674
[TBL] [Abstract][Full Text] [Related]
6. Benefit in lung function improvement and side-effect profile of long-term responders: an analysis of 14 NSCLC patients treated for at least 9 months with gefitinib.
Reck M; Gatzemeier U
Lung Cancer; 2005 Oct; 50(1):107-14. PubMed ID: 15985306
[TBL] [Abstract][Full Text] [Related]
7. Differential efficacy of gefitinib across age groups in treatment of advanced lung adenocarcinoma.
Wang H; Zhang G; Li P; Yan X; Wang Q; Zhu H; Qi G; Fan Q; Ma Z
Pharmazie; 2012 Jan; 67(1):80-5. PubMed ID: 22393836
[TBL] [Abstract][Full Text] [Related]
8. Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II Trial.
Spigel DR; Hainsworth JD; Burkett ER; Burris HA; Yardley DA; Thomas M; Jones SF; Dickson NR; Scullin DC; Bradof JE; Rubinsak JR; Brierre JE; Greco FA
Clin Lung Cancer; 2005 Sep; 7(2):127-32. PubMed ID: 16179100
[TBL] [Abstract][Full Text] [Related]
9. Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity.
Chiu CH; Tsai CM; Chen YM; Chiang SC; Liou JL; Perng RP
Lung Cancer; 2005 Jan; 47(1):129-38. PubMed ID: 15603863
[TBL] [Abstract][Full Text] [Related]
10. Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial.
Cella D; Herbst RS; Lynch TJ; Prager D; Belani CP; Schiller JH; Heyes A; Ochs JS; Wolf MK; Kay AC; Kris MG; Natale RB
J Clin Oncol; 2005 May; 23(13):2946-54. PubMed ID: 15699477
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study.
Jänne PA; Gurubhagavatula S; Yeap BY; Lucca J; Ostler P; Skarin AT; Fidias P; Lynch TJ; Johnson BE
Lung Cancer; 2004 May; 44(2):221-30. PubMed ID: 15084387
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme.
Mu XL; Li LY; Zhang XT; Wang SL; Wang MZ
BMC Cancer; 2004 Aug; 4():51. PubMed ID: 15318946
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor targeted therapy with gefitinib in locally advanced and metastatic primary lung adenocarcinoma.
Liam CK; Pang YK; Leow CH
Respirology; 2006 May; 11(3):287-91. PubMed ID: 16635086
[TBL] [Abstract][Full Text] [Related]
14. Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer.
Argiris A; Mittal N
Lung Cancer; 2004 Mar; 43(3):317-22. PubMed ID: 15165090
[TBL] [Abstract][Full Text] [Related]
15. Skin rash as a surrogate marker of clinical response of targeted therapy using gefitinib in advanced or metastatic non-small-cell lung cancer--a retrospective study.
Acharyya S; Sau S; Dasgupta P; Chakraborty A; Gangopadhyay S
J Indian Med Assoc; 2012 Jul; 110(7):474-6, 493. PubMed ID: 23520673
[TBL] [Abstract][Full Text] [Related]
16. Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy.
Lee DH; Park K; Kim JH; Lee JS; Shin SW; Kang JH; Ahn MJ; Ahn JS; Suh C; Kim SW
Clin Cancer Res; 2010 Feb; 16(4):1307-14. PubMed ID: 20145166
[TBL] [Abstract][Full Text] [Related]
17. Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial.
Sun JM; Lee KH; Kim SW; Lee DH; Min YJ; Yun HJ; Kim HK; Song HS; Kim YH; Kim BS; Hwang IG; Lee K; Jo SJ; Lee JW; Ahn JS; Park K; Ahn MJ;
Cancer; 2012 Dec; 118(24):6234-42. PubMed ID: 22674612
[TBL] [Abstract][Full Text] [Related]
18. High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib.
Omuro AM; Kris MG; Miller VA; Franceschi E; Shah N; Milton DT; Abrey LE
Cancer; 2005 Jun; 103(11):2344-8. PubMed ID: 15844174
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
Kim ST; Uhm JE; Lee J; Sun JM; Sohn I; Kim SW; Jung SH; Park YH; Ahn JS; Park K; Ahn MJ
Lung Cancer; 2012 Jan; 75(1):82-8. PubMed ID: 21684626
[TBL] [Abstract][Full Text] [Related]
20. Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group study.
Asami K; Koizumi T; Hirai K; Ameshima S; Tsukadaira A; Morozumi N; Morikawa A; Atagi S; Kawahara M
Clin Lung Cancer; 2011 Nov; 12(6):387-92. PubMed ID: 21729650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]